AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD
The Swiss pharmaceutical group Novartis AG has launched a study aimed at evaluating the safety, tolerability and efficacy of its Prexige arthritis and pain treatment compared with the non-steroidal anti-inflammatory drugs ibuprofen and nanproxen.
The twelve-month study, called TARGET (Therapeutic Arthritis Research and Gastrointestinal Event Trial), will evaluate more than 18,000 patients worldwide. The …